safinamide has been researched along with 3,7-dimethyl-1-propargylxanthine in 1 studies
| Studies (safinamide) | Trials (safinamide) | Recent Studies (post-2010) (safinamide) | Studies (3,7-dimethyl-1-propargylxanthine) | Trials (3,7-dimethyl-1-propargylxanthine) | Recent Studies (post-2010) (3,7-dimethyl-1-propargylxanthine) |
|---|---|---|---|---|---|
| 199 | 29 | 159 | 202 | 1 | 23 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akkari, R; Borrmann, T; Brunschweiger, A; Drabczyńska, A; Hockemeyer, J; Kieć-Kononowicz, K; Koch, P; Köse, M; Küppers, P; Müller, CE; Radjainia, H; Schlenk, M | 1 |
1 other study(ies) available for safinamide and 3,7-dimethyl-1-propargylxanthine
| Article | Year |
|---|---|
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.
Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine; CHO Cells; Cricetulus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Purinergic P1 Receptor Antagonists; Purines; Xanthines | 2013 |